![E3353_06 [ALT4bxxx].png](https://static.wixstatic.com/media/73af19_0b90f98cbdf94c8b808d8ee2921668a0~mv2.png/v1/fill/w_921,h_928,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/E3353_06%20%5BALT4bxxx%5D.png)
Our proprietary Generative AI & machine learning platform - trained and optimised to identify deeply complex patterns in TCR/antibody immune biomarkers.
Performs
in silico cross reactivity
and derisks developability
Accelerates discovery and engineering
Reproducible
and accurate
By leveraging the diversity of immune repertoires, our AI, governed by biophysics and validated through empirical results, enables the effective design of personalised therapeutics.
Using EMLy we have achieved several world firsts, including the production of a T cell engager with superior properties in record time.
Our discovery platform
Our three-faceted TCR/antibody discovery platform is engineered to compress timelines and deliver rapid, unbiased insights, maximising specificity and efficacy for your immunebased therapy.
With EMLy™ we leverage the power of machine learning to deliver optimal TCRs/Abs using an in-house fine-tuned LLM with agent-based architecture.
EMLy™ links sequence to structure and can infer one from the other to create predictions
Deep neural architecture
ETCEMBLY IS DEVELOPING A PIPELINE OF T CELL ENGAGERS USING GENERATIVE AI
With EMLy™ we leverage the power of ML to deliver optimal TCRs
EMLy™ COMBINES:
= NOVEL TECHNOLOGY FOR IN SILICO
Lab-in-the-loop
We integrate AI/ML, Bioinformatics, Protein Engineering and lab verification to for highly effective, unbiased and rapid prediction and ground truth lab validation cycles
